Boston Scientific BSX Cardiovascular — Net sales of reportable segments

Similar metrics at other companies

MDTCardiovascular — Net Sales

$3.8B+13.8%

NATRCardiovascular — Net Sales

$19.83M+1.9%

MDTCardiovascular — Reportable segment operating profit

$1.07B+11.8%

GLW

GLWTotal Reportable Segments — Segment net sales

$4.44B+20.1%

AOSReportable Segments — Net Sales

$945.6M-1.9%

MDTReportable segment net sales — Net Sales

$6.66B+8.5%

FAQ

What is Boston Scientific's cardiovascular — net sales of reportable segments?

Boston Scientific (BSX) reported cardiovascular — net sales of reportable segments of $3.62B in Q2 2026.

How has Boston Scientific's cardiovascular — net sales of reportable segments changed year-over-year?

Boston Scientific's cardiovascular — net sales of reportable segments increased by 8.5% year-over-year, from $3.34B to $3.62B.

What is the long-term trend for Boston Scientific's cardiovascular — net sales of reportable segments?

Over 4 years (2021 to 2025), Boston Scientific's cardiovascular — net sales of reportable segments has grown at a 18.6% compound annual growth rate (CAGR), from $6.72B to $13.29B.

What does cardiovascular — net sales of reportable segments mean?

Represents the total revenue generated from the sale of cardiovascular medical devices to external customers. It is a primary indicator of the segment's market demand and competitive success in the cardiovascular sector.